Amneal debuts generic Esomeprazole strontium in USA

7 January 2014

Privately-held US generics drugmaker Amneal Pharmaceuticals has announced the launch of generic esomeprazole strontium delayed-release capsules 49.3mg. This new esomeprazole therapy is the generic equivalent of the recently launched brand Esomeprazole strontium.

It contains the same active moiety (esomeprazole) in a different salt form as found in the leading proton pump inhibitor brand Nexium (esomeprazole magnesium) from Anglo-Swedish drug major AstraZeneca (LSE: AZN) and presents a potentially more affordable treatment option for gastroesophageal reflux disease (GERD) in adult patients, says Amneal.

Esomeprazole strontium capsules will be sold in 30-count bottles and are the authorized generic equivalent for their branded counterpart by the same name (Esomeprazole strontium delayed-release capsules 49.3mg), which Amneal launched in December 2013.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics